Takeda's First-in-Class Narcolepsy Drug ORZEYFUL Launches in Japan, China
TAK sits 46% above its 52-week low of $12.99.
Summary
Takeda announced the commercial launch of ORZEYFUL (oveporexton) in Japan and China for Narcolepsy Type 1. This first-in-class orexin receptor 2 agonist targets the underlying cause of the disease. This follows the FDA approval of ORZEYFUL in the US on August 6th, marking a significant commercialization milestone for Takeda in two major pharmaceutical markets. The launch expands the drug's global availability and is expected to contribute to future revenue streams.
At the time of this announcement, TAK was trading at $18.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $60.1B. The 52-week trading range was $12.99 to $19.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.